ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives $7.14 Consensus Price Target from Analysts

ProQR Therapeutics N.V. (NASDAQ:PRQR) has been assigned an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $7.1429.

A number of equities analysts have weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Thursday, January 22nd. Zacks Research upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. Finally, Chardan Capital reiterated a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a report on Tuesday, November 4th.

ProQR Therapeutics Trading Down 2.1%

Shares of PRQR opened at $1.39 on Tuesday. The firm has a market cap of $146.24 million, a P/E ratio of -2.96 and a beta of 0.20. ProQR Therapeutics has a 12 month low of $1.07 and a 12 month high of $3.10. The stock’s 50 day moving average is $1.88 and its two-hundred day moving average is $2.14.

Institutional Trading of ProQR Therapeutics

Several large investors have recently made changes to their positions in the company. Jane Street Group LLC lifted its holdings in ProQR Therapeutics by 699.3% in the 1st quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 79,720 shares in the last quarter. Vontobel Holding Ltd. raised its position in shares of ProQR Therapeutics by 76.5% in the second quarter. Vontobel Holding Ltd. now owns 63,979 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 27,722 shares during the last quarter. Sio Capital Management LLC lifted its stake in shares of ProQR Therapeutics by 1.0% in the second quarter. Sio Capital Management LLC now owns 2,075,139 shares of the biopharmaceutical company’s stock worth $4,233,000 after buying an additional 20,546 shares in the last quarter. Walleye Capital LLC boosted its position in ProQR Therapeutics by 5.6% during the second quarter. Walleye Capital LLC now owns 531,977 shares of the biopharmaceutical company’s stock worth $1,085,000 after acquiring an additional 28,413 shares during the last quarter. Finally, Affinity Asset Advisors LLC grew its stake in ProQR Therapeutics by 6.5% during the 2nd quarter. Affinity Asset Advisors LLC now owns 3,499,512 shares of the biopharmaceutical company’s stock valued at $7,139,000 after acquiring an additional 215,000 shares in the last quarter. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.